- Home
- FEBO vs MBRX Comparison
FEBO vs MBRX Comparison
Compare FEBO & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FEBO | MBRX |
|---|---|---|
| Founded | 1993 | 2015 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.4M | 6.4M |
| IPO Year | 2022 | 2016 |
Fundamental Metrics
Financial Performance| Metric | FEBO | MBRX |
|---|---|---|
| Price | $0.68 | $8.73 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $240.00 |
| AVG Volume (30 Days) | 4.8K | ★ 206.0K |
| Earning Date | 05-15-2026 | 11-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.61 | $0.16 |
| 52 Week High | $1.46 | $12.65 |
Technical Indicators
Market Signals| Indicator | FEBO | MBRX |
|---|---|---|
| Relative Strength Index (RSI) | 52.95 | 80.14 |
| Support Level | $0.65 | $2.12 |
| Resistance Level | $0.80 | $10.24 |
| Average True Range (ATR) | 0.08 | 0.99 |
| MACD | 0.01 | 0.16 |
| Stochastic Oscillator | 70.51 | 72.00 |
Price Performance
Historical ComparisonAbout FEBO Fenbo Holdings Limited
Fenbo Holdings Ltd is a company engaged in producing premium personal care electric appliances, principally electrical hair styling products such as straighteners, curlers, trimmers, etc., and toy products to overseas markets. It manufactures and sells products such as Straightener, Mini Straightener, and Curling Iron.
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.